PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy

RA Hegele, H Cao, C Frankowski, ST Mathews… - Diabetes, 2002 - diabetesjournals.org
RA Hegele, H Cao, C Frankowski, ST Mathews, T Leff
Diabetes, 2002diabetesjournals.org
Autosomal dominant familial partial lipodystrophy (FPLD) due to mutant LMNA encoding
nuclear lamin A/C is characterized by adipose tissue repartitioning together with multiple
metabolic disturbances, including insulin resistance and dyslipidemia. There is emerging
evidence that some rare mutations in peroxisome proliferator-activated receptor-γ (PPAR-γ),
encoded by PPARG, might be associated with human lipodystrophy. We report a three-
generation Canadian kindred ascertained based upon partial lipodystrophy, with a normal …
Autosomal dominant familial partial lipodystrophy (FPLD) due to mutant LMNA encoding nuclear lamin A/C is characterized by adipose tissue repartitioning together with multiple metabolic disturbances, including insulin resistance and dyslipidemia. There is emerging evidence that some rare mutations in peroxisome proliferator-activated receptor-γ (PPAR-γ), encoded by PPARG, might be associated with human lipodystrophy. We report a three-generation Canadian kindred ascertained based upon partial lipodystrophy, with a normal LMNA gene sequence. Candidate gene sequencing showed that all four affected subjects were heterozygous for a novel T→A mutation at PPARG nucleotide 1164 in exon 5 that predicted substitution of phenylalanine at codon 388 by leucine (F388L). The mutation was absent from normal family members and normal unrelated subjects, and altered a highly conserved residue within helix 8 of the predicted ligand-binding pocket of PPAR-γ. The mutant receptor had significantly decreased basal transcriptional activity and impaired stimulation by a synthetic ligand. The germline transmission of a transactivation-deficient mutation in PPARG suggests that autosomal dominant partial lipodystrophy is genetically heterogeneous. Our findings are consistent with the idea that mutant PPARG can underlie the partial lipodystrophy phenotype.
diabetesjournals.org